Abstract:Teshome Belachew, 1 Seid Yaheya, 2 Nehemia Tilahun, 2 Eshet Gebrie, 2 Rim Seid, 2 Tilahun Nega, 3 Sirak Biset 1 1 Department of Medical Microbiology, School of Biomedical and Laboratory Sciences, University of Gondar, Gondar, Ethiopia; 2 School of Biomedical and Laboratory Sciences, University of Gondar, Gondar, Ethiopia; 3 University of Gondar Comprehensive Specialized Hospital, Gondar, Ethiopia Correspondence: Sirak Biset, Tel +251-911-598-568, Email Background: Multidrug-resistant tuberculosis (MDR-TB) remains a public health crisis and a health security threat worldwide. Poor public health infrastructure, inefficient infection control and mismanagement of TB treatment are among the reasons for the continuous emergence and spread of drug-resistant TB (DR-TB). The final treatment outcome is the most direct measurement of TB control programs. Therefore, this study sought to determine the proportions and predictors of TB treatment outcomes among MDR/RR-TB treated patients. Methods: A 10-year, 2011 to 2021, hospital-based retrospective cohort study was conducted at the University of Gondar Comprehensive Specialized Hospital. The records of 408 MDR-TB patients, 389 with treatment outcome and 19 on treatment, were collected using a structured checklist. Results: A total of 389 patients with a recorded MDR/RR-TB treatment outcome were included. The treatment success rate was 77.12%, with 58.35% cured and 18.76% treatment completed. The proportion of death rate, treatment default loss to follow-up, treatment failure, and unknown treatment outcome was 9.25%, 6.94%, 3.1%, and 3.6%, respectively. Regarding the patient category, the most successful treatment outcome (83.5%) came from patients diagnosed with relapse cases, followed by new cases (81.8%). An unsuccessful treatment outcome was significantly associated with patients aged > 44 years (AOR, 3.3, 95% CI = 1.55– 6.99). Conclusion and Recommendations: This study indicated that nearly 23% of MDR/RR-TB patients had unsuccessful treatment outcomes and being older was significantly correlated with these outcomes. For better outcomes, it is recommended to strengthen combined treatment adherence interventions and evaluate treatment regimens and administration options. A prospective cohort study may be required to investigate the full range of potential causes of unfavorable outcomes. Keywords: tuberculosis treatment outcome, multidrug-resistant tuberculosis, rifampicin resistance, Ethiopia Tuberculosis (TB) is one of the top causes of morbidity and mortality worldwide, particularly in developing countries. 1,2 TB caused by Mycobacterium tuberculosis (MTB), a bacterium that can survive harsh environments mainly due to the presence of an unusually thick, lipid-rich cell envelope, 3,4 infects approximately 1/4 of the world's population. 5 Although, the global incidence and death rates of TB have decreased in recent years, 5,6 meeting the WHO End TB Strategy targets is becoming increasingly difficult. 7 The emergence of drug-resistant (DR) MTB strains is an impediment to effective TB control programs, 5,6,8 which could explain the setback. 2,9,10 DR-TB, responsible for roughly one-third of all antimicrobial resistance deaths worldwide, 11 is a public health crisis that poses a threat to global health security. In 2019, around 1.5 million DR-TB cases were reported worldwide. 5 Both mismanagement of TB treatment and person-to-person transmission are the primary reasons for the continued emergence and spread of DR-TB. 8,12,13 Multidrug-resistant TB (MDR-TB), TB resistant to at least isoniazid and rifampicin, and rifampicin-resistant (RR) TB, TB resistant to rifampicin with or without resistance to other first-line anti-TB drugs, are the most common types of DR-TB. 14 According to the reports, up to 90% of RR-TB cases are resistant to isoniazid. 15 As a result, in countries with limited MDR-TB laboratory diagnostic capacity, RR-TB is utilized as a surrogate marker for MDR-TB. 16 Globally, 3–4% of new and 18–21% of previously treated cases are diagnosed with MDR/RR-TB. 5,6 However, in Ethiopia, the prevalence of RR-TB and MDR-TB in 2019 was 1.1% and 1.03% among new and 7.5% and 6.52% among previously treated TB cases, respectively. 16 Globally, an estimated of nearly half a million new cases of MDR/RR-TB emerge each year, requiring regimens that include second-line drugs, which are less effective, more expensive, and more toxic than the first-line drugs. 5,14,17 Even though the annual number of people taking treatment for -Abstract Truncated-

Treatment outcomes of standardized injectable shorter regimen for multi-drugs resistant tuberculosis in Ethiopia: a retrospective cohort study

Treatment outcomes and associated factors among patients with multidrug-resistant tuberculosis in Southwestern Oromia, Ethiopia: ten-year retrospective analysis

Multidrug-resistant tuberculosis treatment outcomes and associated factors at Yirgalem General Hospital, Sidama Region, South Ethiopia: a retrospective cohort study

Drug-resistant tuberculosis care and treatment outcomes over the last 15 years in Ethiopia: Results from a mixed-method review of trends

Multidrug-Resistant Tuberculosis Treatment Outcome and Associated Factors at the University of Gondar Comprehensive Specialized Hospital: A Ten-Year Retrospective Study

Treatment Outcome of MDR/RR TB in a Resource-Constrained Setup: A Four-Year Retrospective Analysis

Treatment outcomes for isoniazid-monoresistant tuberculosis in Peru, 2012-2014

Tuberculosis treatment outcome and associated factors among tuberculosis patients at Wolayta Sodo Teaching and Referral Hospital, Southern Ethiopia: a retrospective study

Determinants of unsuccessful tuberculosis treatment outcome in Southwest Ethiopia regional state public hospitals, 2022: a multi-center case control study

Effectiveness and safety of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis: a prospective cohort study

Nutritional status and treatment outcomes of tuberculosis in Mizan Tepi University Teaching Hospital, a five -year retrospective study

Implementation of multidrug-resistant tuberculosis (MDR-TB) treatment in Gabon: lessons learnt from the field

Adverse drug reactions and treatment outcome analysis of DOTS-plus therapy of MDR-TB patients at district tuberculosis centre: A four year retrospective study

Intermittent treatment interruption and its effect on multidrug resistant tuberculosis treatment outcome in Ethiopia

Impacts of body weight change on treatment outcomes in patients with multidrug-resistant tuberculosis in Northwest Ethiopia

Tuberculosis treatment outcomes and associated factors among tuberculosis patients treated at healthcare facilities of Motta Town, Northwest Ethiopia: a five-year retrospective study

Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial

Management of rifampicin-resistant tuberculosis in conflict-affected areas: The case of Iraq

Delays to treatment initiation and emergence of drug resistance among new adult tuberculosis patients in Tigray, Northern Ethiopia

Treatment Outcomes of Multidrug-Resistant Tuberculosis Patients Receiving Ambulatory Treatment in Shenzhen, China: a Retrospective Cohort Study.

Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis